<SEC-DOCUMENT>0001437749-24-020336.txt : 20240614
<SEC-HEADER>0001437749-24-020336.hdr.sgml : 20240614
<ACCEPTANCE-DATETIME>20240614160957
ACCESSION NUMBER:		0001437749-24-020336
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20240614
DATE AS OF CHANGE:		20240614

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CervoMed Inc.
		CENTRAL INDEX KEY:			0001053691
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				300645032
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-279343
		FILM NUMBER:		241044826

	BUSINESS ADDRESS:	
		STREET 1:		20 PARK PLAZA
		STREET 2:		SUITE 424
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
		BUSINESS PHONE:		(617) 744-4400

	MAIL ADDRESS:	
		STREET 1:		20 PARK PLAZA
		STREET 2:		SUITE 424
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Diffusion Pharmaceuticals Inc.
		DATE OF NAME CHANGE:	20160115

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RestorGenex Corp
		DATE OF NAME CHANGE:	20140307

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Stratus Media Group, Inc
		DATE OF NAME CHANGE:	20080722
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>crvo20240613e_424b3.htm
<DESCRIPTION>FORM 424B3
<TEXT>
<html><head>
	<title>crvo20240613e_424b3.htm</title>

	<!-- Generated by ThunderDome Portal - 6/14/2024 7:05:41 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Filed pursuant to Rule 424(b)(3)</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Registration No.: 333-279343</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>PROSPECTUS SUPPLEMENT No. 1</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>(To the Prospectus dated June 5, 2024)</b></p>

<div style="text-align: center;"><img alt="crvo.jpg" src="crvo.jpg"></div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:36pt;"><b>5,064,570 Shares of Common Stock</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">This prospectus supplement No. 1 (the &#8220;Prospectus Supplement&#8221;) amends and supplements our prospectus contained in our Registration Statement on Form S-1, effective as of June 5, 2024 (the &#8220;Prospectus&#8221;), related to the resale by the selling stockholders identified in the Prospectus of up to an aggregate of 5,064,570 shares of our common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">This Prospectus Supplement is being filed in order to incorporate into and include in the Prospectus the information contained in our attached Current Report on Form 8-K, filed with the Securities and Exchange Commission on June 14, 2024.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">This Prospectus Supplement should be read in conjunction with the Prospectus and is qualified by reference to the Prospectus except to the extent that the information in this Prospectus Supplement supersedes the information contained therein.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our Common Stock is listed on the NASDAQ Capital Market under the symbol &#8220;CRVO.&#8221; The last reported closing price of our Common Stock on the NASDAQ Capital Market on June 13, 2024, was $19.76.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b>Investing in our securities involves risks. See </b>&#8220;<b>Risk Factors</b>&#8221;<b> beginning on page 9 of the Prospectus and in the documents incorporated by reference in the Prospectus for a discussion of the factors you should carefully consider before deciding to purchase these securities.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto">
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">The date of this Prospectus Supplement is June 14, 2024.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0">
<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0">
<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt;"><b>UNITED STATES</b></p>

<p style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Washington, D.C. 20549</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto">
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt;"><b>FORM 8-K</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto">
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CURRENT REPORT</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Pursuant to Section 13 or 15(d)</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>of The Securities Exchange Act of 1934</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>June 11, 2024</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Date of Report (Date of earliest event reported)</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto">
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:24pt;font-variant:normal;text-align:center;margin:0pt;"><b>CervoMed Inc.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Exact name of registrant as specified in its charter)</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto">
<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: top; width: 33%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Delaware</b></p>
			</td>
			<td style="vertical-align: top; width: 33%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>001-37942</b></p>
			</td>
			<td style="vertical-align: top; width: 33%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>30-0645032</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 33%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(State or other jurisdiction</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>of incorporation)</b></p>
			</td>
			<td style="vertical-align: top; width: 33%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Commission</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>File Number)</b></p>
			</td>
			<td style="vertical-align: top; width: 33%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(I.R.S. Employer</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Identification No.)</b></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td colspan="3" style="vertical-align: middle; width: 50%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: middle; width: 50%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align: top; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>20 Park Plaza, Suite 424</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Boston, Massachusetts</b></p>
			</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>02116</b></p>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align: top; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Address of principal executive offices)</b></p>
			</td>
			<td style="vertical-align: top; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Zip Code)</b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>s telephone number, including area code: (617) 744-4400</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Not applicable</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Former name or former address, if changed since last report)</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto">
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9744;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9744;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9744;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9744;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Title of each class</b></p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Trading</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Symbol(s)</b></p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Name of each exchange</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>on which registered</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Common Stock, $0.001 par value</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">CRVO</p>
			</td>
			<td style="vertical-align:bottom;width:auto;">&nbsp;</td>
			<td style="vertical-align:top;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">NASDAQ Capital Market</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Emerging growth company &#9744;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">&nbsp;</p>

<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0">
<hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0">
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 54pt;text-indent:-54pt;"><b>Item 5.07</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Submission of Matters to a Vote of Security Holders</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The 2024 Annual Meeting of Stockholders (the &#8220;Annual Meeting&#8221;) of CervoMed Inc. (the &#8220;Company&#8221; or &#8220;we&#8221;) was held on June 14, 2024. Stockholders of record at the close of business on April 29, 2024 (the &#8220;Record Date&#8221;), were entitled to vote at the Annual Meeting and, as of the Record Date, there were 8,253,741 shares of the Company&#8217;s common stock outstanding. At the Annual Meeting, the holders of [______] shares were present, virtually or by proxy, representing approximately [____]% of the shares outstanding as of the Record Date and, accordingly, a quorum was present at the Annual Meeting.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The matters submitted to the Company&#8217;s stockholders and voted upon at the meeting, which are more fully described in the Company&#8217;s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 29, 2024 (the &#8220;Proxy Statement&#8221;), as well as the results of each such vote were as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 9pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(1)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Proposal No. 1 &#8211;&nbsp;To elect eight persons to serve as directors until the Company&#8217;s next Annual Meeting of Stockholders or until their respective successors are elected and qualified.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The election of each nominee pursuant to Proposal No. 1 required the affirmative vote of a plurality of the votes present and entitled to vote at the Annual Meeting and, accordingly, each nominee received the requisite number of votes for election at the Annual Meeting.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:14.4%;">&nbsp;</td>
			<td colspan="2" style="border-bottom:solid 1px #000000;vertical-align:bottom;width:10.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">For</p>
			</td>
			<td colspan="2" style="border-bottom:solid 1px #000000;vertical-align:bottom;width:8.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Withheld</p>
			</td>
			<td colspan="2" style="border-bottom:solid 1px #000000;vertical-align:top;width:12.9%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Broker Non-Votes</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:14.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">John Alam, M.D.</p>
			</td>
			<td style="vertical-align:bottom;width:4.6%;">5,643,630</td>
			<td style="vertical-align:bottom;width:5.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4%;">5,819</td>
			<td style="vertical-align:bottom;width:4.7%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.4%;">817,650</td>
			<td style="vertical-align:bottom;width:8.5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:top;width:14.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Joshua S. Boger, Ph.D.</p>
			</td>
			<td style="vertical-align:bottom;width:4.6%;">5,642,786</td>
			<td style="vertical-align:bottom;width:5.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4%;">6,663</td>
			<td style="vertical-align:bottom;width:4.7%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.4%;">817,650</td>
			<td style="vertical-align:top;width:8.5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:14.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Robert J. Cobuzzi, Ph.D.</p>
			</td>
			<td style="vertical-align:bottom;width:4.6%;">5,080,602</td>
			<td style="vertical-align:bottom;width:5.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4%;">568,502</td>
			<td style="vertical-align:bottom;width:4.7%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.4%;">817,995</td>
			<td style="vertical-align:top;width:8.5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:top;width:14.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Sylvie Gr&#233;goire, PharmD.</p>
			</td>
			<td style="vertical-align:bottom;width:4.6%;">5,632,705</td>
			<td style="vertical-align:bottom;width:5.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4%;">16,399</td>
			<td style="vertical-align:bottom;width:4.7%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.4%;">817,995</td>
			<td style="vertical-align:bottom;width:8.5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:14.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Jane H. Hollingsworth, J.D.</p>
			</td>
			<td style="vertical-align:bottom;width:4.6%;">5,404,381</td>
			<td style="vertical-align:bottom;width:5.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4%;">244,813</td>
			<td style="vertical-align:bottom;width:4.7%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.4%;">817,905</td>
			<td style="vertical-align:top;width:8.5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:top;width:14.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Jeff Poulton</p>
			</td>
			<td style="vertical-align:bottom;width:4.6%;">5,639,899</td>
			<td style="vertical-align:bottom;width:5.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4%;">9,550</td>
			<td style="vertical-align:bottom;width:4.7%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.4%;">817,650</td>
			<td style="vertical-align:bottom;width:8.5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:14.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Marwan Sabbagh, M.D.</p>
			</td>
			<td style="vertical-align:bottom;width:4.6%;">5,641,273</td>
			<td style="vertical-align:bottom;width:5.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4%;">8,176</td>
			<td style="vertical-align:bottom;width:4.7%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.4%;">817,650</td>
			<td style="vertical-align:bottom;width:8.5%;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align:top;width:14.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Frank Zavrl</p>
			</td>
			<td style="vertical-align:bottom;width:4.6%;">5,638,435</td>
			<td style="vertical-align:bottom;width:5.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4%;">11,014</td>
			<td style="vertical-align:bottom;width:4.7%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.4%;">817,650</td>
			<td style="vertical-align:bottom;width:8.5%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 9pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(2)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Proposal No. 2 &#8211;&nbsp;To ratify the selection of RSM US LLP as the Company&#8217;s independent registered public accounting firm for the year ending December 31, 2024.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The approval of Proposal No. 2 required the affirmative vote of a majority of the&nbsp;votes present and entitled to vote at the Annual Meeting and, accordingly, Proposal No. 2 received the requisite number of votes for approval at the Annual Meeting.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:12.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">For</p>
			</td>
			<td colspan="2" style="border-bottom:solid 1px #000000;vertical-align:bottom;width:19.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Against</p>
			</td>
			<td colspan="2" style="border-bottom:solid 1px #000000;vertical-align:bottom;width:14.7%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Abstain</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:bottom;width:12.3%;">6,457,067</td>
			<td style="vertical-align:bottom;width:5.5%;">8,463</td>
			<td style="vertical-align:bottom;width:13.8%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:4.4%;">1,569</td>
			<td style="vertical-align:bottom;width:10.3%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 9pt;">&nbsp;</td>
			<td style="width: 18pt;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;margin:0pt;">(3)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: 'Times New Roman', Times, serif;font-size: 10pt;font-variant:normal;text-align:justify;margin:0pt;">Proposal No. 3 &#8211;&nbsp;To approve, on an advisory basis, the compensation of the Company&#8217;s named executive officers during the year ended December 31, 2023, as disclosed in the Proxy Statement.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The approval of Proposal No. 3 required the affirmative vote of a majority of the&nbsp;votes present and entitled to vote at the Annual Meeting and, accordingly, Proposal No. 3 received the requisite number of votes for approval at the Annual Meeting.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:8.8%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">For</p>
			</td>
			<td colspan="2" style="border-bottom:solid 1px #000000;vertical-align:bottom;width:13.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Against</p>
			</td>
			<td colspan="2" style="border-bottom:solid 1px #000000;vertical-align:bottom;width:15.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Abstain</p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:8.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Broker Non-Votes</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align:top;width:8.8%;">5,624,207</td>
			<td style="vertical-align:bottom;width:4.1%;">20,057</td>
			<td style="vertical-align:bottom;width:9.5%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:3.4%;">5,185</td>
			<td style="vertical-align:bottom;width:11.9%;">&nbsp;</td>
			<td style="vertical-align:top;width:8.6%;">817,650</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 8.01</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Other Events</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On June 11, 2024, the Company issued a press release announcing the completion of enrollment in its Phase 2b RewinD-LB clinical trial of neflamapimod for the treatment of patients with dementia with Lewy bodies. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 54pt;text-indent:-54pt;"><b>Item 9.01</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Financial Statements and Exhibits</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>(d)</i></b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><i>Exhibits</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:bottom;width:11.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Exhibit No.</b></p>
			</td>
			<td style="vertical-align:bottom;width:3.3%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 85.2%; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Description</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:middle;width:11.5%;">&nbsp;</td>
			<td style="vertical-align:middle;width:3.3%;">&nbsp;</td>
			<td style="vertical-align:middle;width:85.2%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:11.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">99.1</p>
			</td>
			<td style="vertical-align:top;width:3.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:85.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_688532.htm" style="-sec-extract:exhibit;">Press Release, issued June 11, 2024</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:11.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">104</p>
			</td>
			<td style="vertical-align:top;width:3.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:85.2%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:11.5%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.3%;">&nbsp;</td>
			<td style="vertical-align:top;width:85.2%;">&nbsp;</td>
		</tr>

</table>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SIGNATURES</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="text-indent: 0; width: 100%;font-family: 'Times New Roman', Times, serif; font-size: 10pt">

		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Date: June 14, 2024&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
			</td>
			<td colspan="2" valign="top" width="38%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b>CervoMed Inc.</b></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td align="left" nowrap="nowrap" valign="bottom" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td align="left" style="text-align: left;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="text-align: left" valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">By: </font></p>
			</td>
			<td align="left" nowrap="nowrap" style="BORDER-BOTTOM: #000000 1px solid" valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">/s/&nbsp;</font>William Elder</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">William Elder</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Chief Financial Officer &amp; General Counsel</p>
			</td>
			<td valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 252pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex_688532.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html><head>
	<title>ex_688522.htm</title>

	<!-- Generated by ThunderDome Portal - 6/14/2024 2:31:26 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 99.1</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font><img alt="cervomed01.jpg" src="cervomed01.jpg"></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>- Topline data expected in December 2024 - </i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>- Phase 2b design optimized for success; clear path to market in this high value indication expected with positive result -</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Boston </b>&#8211;<b> June 11, 2024 </b>&#8211; CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that it has completed enrollment in RewinD-LB, a Phase 2b trial evaluating neflamapimod in patients with dementia with Lewy bodies (DLB).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#8220;Drug development for the major dementias over the past decade has progressively focused on earlier stages of disease. In our phase 2a data with neflamapimod in patients with DLB, the treatment response in patients with pure DLB was substantial and greater than the response seen in patients who had biomarker evidence of Alzheimer&#8217;s disease (AD)-related co-pathology, the latter representing patients with more advanced disease,&#8221; said John Alam, MD, Chief Executive Officer of CervoMed. &#8220;The completion of enrollment demonstrates, for the first time, the feasibility of enrolling a pure DLB patient population into an adequately powered trial. The expeditious nature of the enrollment reflects the level of engagement across our clinical trial sites and the execution of our clinical team and partners, as well as the finding that most patients who entered into screening did not have AD-related co-pathology, as measured by plasma ptau181 testing. We expect to report topline data in December 2024, which we believe will bring us one step closer to potentially delivering the first DLB specific FDA-approved therapy.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Kelly Blackburn, CervoMed&#8217;s SVP of Clinical Development, added, &#8220;Completing enrollment in the RewinD-LB trial marks a significant milestone and I would like to congratulate the CervoMed team and our partners, and most importantly, thank the patients and their families for participating in the neflamapimod clinical development program. The rapid pace of enrollment once all sites were activated points to the high unmet medical need and patient interest in novel treatments for DLB.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Eligibility criteria to be randomized included: (1) a diagnosis of DLB by consensus criteria, (2) Clinical Dementia Rating Global Score (CDR-GS) of 0.5 or 1.0, and (3) absence of AD co-pathology, as evidenced by plasma phosphorylated tau at position 181 (ptau181) of less than the protocol-defined cutoff of 2.4 pg/mL. Approximately two-thirds of patients undergoing ptau181 testing met the associated eligibility criteria, with no difference in the rate of eligibility between patients with CDR-GS=0.5 and those with CDR-GS=1.0.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>About the RewinD-LB Phase 2b Study in Dementia with Lewy Bodies </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">CervoMed&#8217;s ongoing Phase 2b study, RewinD-LB, is a randomized, 16-week, double-blind, placebo-controlled clinical trial evaluating oral neflamapimod (40mg TID) in up to 160 patients with very mild or mild dementia due to DLB. Patients completing the 16-week placebo-controlled study period will be able to continue in the study while receiving open label neflamapimod treatment for an additional 32 weeks. Patients with Alzheimer&#8217;s Disease-related co-pathology, assessed by a blood biomarker (plasma ptau181), will be excluded. The primary endpoint in the study is change in the Clinical Dementia Rating Sum of Boxes, and secondary endpoints include the Timed Up and Go test, a cognitive test battery, and the Clinician&#8217;s Global Impression of Change. The RewinD-LB study is funded by a&nbsp;$21.0 million&nbsp;grant from the&nbsp;National Institutes&nbsp;of Health&#8217;s&nbsp;National Institute on Aging, which will be disbursed over the course of the study as costs are incurred. The study includes 43 sites (32 in&nbsp;the United States, eight in the&nbsp;United Kingdom, and three in&nbsp;the Netherlands), all of which have been initiated. More information on the RewinD-LB study, including contact information on active clinical trial sites, is available at&nbsp;<u>clinicaltrials.gov</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div><img alt="cervomed01.jpg" src="cervomed01.jpg"></div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Forward-Looking Statements</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">This press release includes express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, regarding the intentions, plans, beliefs, expectations or forecasts for the future of CervoMed Inc. (the Company), including, but not limited to, the therapeutic potential of neflamapimod, the anticipated timing and achievement of clinical and development milestones, including the completion and achievement of primary endpoints of the RewinD-LB Phase 2b clinical trial and the Company&#8217;s announcement of topline data therefrom, any other expected or implied benefits or results, including that any initial clinical results observed with respect to neflamapimod in the RewinD-LB Trial will be replicated in later trials, and the Company&#8217;s clinical development plans. Terms such as &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;aims,&#8221; &#8220;seeks,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;could,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;approximately,&#8221; &#8220;potential,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;predict,&#8221; &#8220;forecast,&#8221; &#8220;continue,&#8221; or other words that convey uncertainty of future events or outcomes (including the negative of these terms) may identify these forward-looking statements. Although there is believed to be reasonable basis for each forward-looking statement contained herein, forward-looking statements by their nature involve risks and uncertainties, known and unknown, many of which are beyond the Company&#8217;s control and, as a result, actual results could differ materially from those expressed or implied in any forward-looking statement. Particular risks and uncertainties include, among other things, those related to: the Company&#8217;s available cash resources and the availability of additional funds on acceptable terms; the results of the Company&#8217;s clinical trials, including RewinD-LB; the likelihood and timing of any regulatory approval of neflamapimod or the nature of any feedback the Company may receive from the U.S. Food and Drug Administration; the ability to implement business plans, forecasts, and other expectations in the future; general economic, political, business, industry, and market conditions, inflationary pressures, and geopolitical conflicts; and the other factors discussed under the heading &#8220;Risk Factors&#8221; in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the U.S. Securities and Exchange Commission (SEC) on March 29, 2024, and other filings that the Company may file from time to time with the SEC. Any forward-looking statements in this press release speak only as of the date hereof (or such earlier date as may be identified). The Company does not undertake any obligation to update such forward-looking statements to reflect events or circumstances after the date of this press release, except to the extent required by law.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Investor Contact: </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">PJ Kelleher</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">LifeSci Advisors</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Investors@cervomed.com</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">617-430-7579</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>cervomed01.jpg
<TEXT>
begin 644 cervomed01.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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M)7POXBU&VMQS]BOP+FV)]APRY]5/X5W7AR35)K ?VM#:0708C%M(SQL!T/S
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M8_M5_%"ZMU2Z\<:1J.G64A7!^R65LZG'^R9I)/\ OBN;_P""W?\ P1C^-WQ
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M73L;E%%%?.GK!7P'_P '!_[-#?'/]FCPKK[++-8^ ];-YJ$,8Y>WFC,3$GL
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@ !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>crvo.jpg
<TEXT>
begin 644 crvo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 L17AI9@  34T *@    @  0$Q  (
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M#%>7;B-VRT<9VJ!Z>]:^S?*Y/8\RMF5&G4]FG=GOR.DBAD<,#R"#G-/S7/\
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M)XBXP<;3U!&:FI*%W&]4>6:C\#]-F\6#7M(U&XTN99!*L< 7:K9ZCC]*]*N
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M7LR8)%].X_G78>(-'@U_P_>:7=@&.YB,9]CV/YXKYS\&:_??"'Q]<Z-K:/\
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MB]1]:^A])_: \/66BV5I+87K/!;QQL5 P2J@?TK?$PE)JQG3DEN>W,X1"S$
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J1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
